Limits...
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.

Cella D, Davis MP, Négrier S, Figlin RA, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ - Cancer (2014)

Bottom Line: M1 demonstrated that the initial increase in patient-reported fatigue with sunitinib was worst during cycle 1, with mean values numerically better at subsequent cycles; most pairwise comparisons of consecutive CTCAE fatigue cycle means were not found to be statistically significant.The majority of HRQoL scores were better with sunitinib versus IFN-α for the same CTCAE fatigue grade.Patients reported worse fatigue during the first sunitinib cycle.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Show MeSH

Related in: MedlinePlus

Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 long-form questionnaire is shown.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4231253&req=5

fig01: Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 long-form questionnaire is shown.

Mentions: As previously reported,6,14 HRQoL was assessed during the study using 3 psychometrically tested patient self-reported questionnaires: the Functional Assessment of Cancer Therapy-Kidney Symptom Index–15-item (FKSI-15) (Fig. 1),15 the Functional Assessment of Cancer Therapy-General (FACT-G),16 and the EuroQoL Group's 5-dimension (EQ-5D) questionnaire.17 Patients completed the questionnaires on days 1 and 28 of each treatment cycle (reflecting sunitinib's intermittent treatment schedule) to measure HRQoL across the full course of therapy, both during active treatment and after a treatment break, and at the end of treatment or study withdrawal. HRQoL scores were averaged for each patient by cycle.


Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.

Cella D, Davis MP, Négrier S, Figlin RA, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ - Cancer (2014)

Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 long-form questionnaire is shown.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4231253&req=5

fig01: Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 long-form questionnaire is shown.
Mentions: As previously reported,6,14 HRQoL was assessed during the study using 3 psychometrically tested patient self-reported questionnaires: the Functional Assessment of Cancer Therapy-Kidney Symptom Index–15-item (FKSI-15) (Fig. 1),15 the Functional Assessment of Cancer Therapy-General (FACT-G),16 and the EuroQoL Group's 5-dimension (EQ-5D) questionnaire.17 Patients completed the questionnaires on days 1 and 28 of each treatment cycle (reflecting sunitinib's intermittent treatment schedule) to measure HRQoL across the full course of therapy, both during active treatment and after a treatment break, and at the end of treatment or study withdrawal. HRQoL scores were averaged for each patient by cycle.

Bottom Line: M1 demonstrated that the initial increase in patient-reported fatigue with sunitinib was worst during cycle 1, with mean values numerically better at subsequent cycles; most pairwise comparisons of consecutive CTCAE fatigue cycle means were not found to be statistically significant.The majority of HRQoL scores were better with sunitinib versus IFN-α for the same CTCAE fatigue grade.Patients reported worse fatigue during the first sunitinib cycle.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Show MeSH
Related in: MedlinePlus